Literature DB >> 7985674

Lipoprotein glomerulopathy: first report in a Chinese male.

P Zhang1, R Matalon, L Kaplan, A Kumar, G Gallo.   

Abstract

Only seven patients with lipoprotein glomerulopathy have been reported, all in Japanese subjects. We describe the first Chinese patient with lipoprotein glomerulopathy, a 28-year-old man followed for 8 years. As in all patients described thus far, our patient has hyperlipoproteinemia phenotypically similar to the familial type III hyperlipoproteinemia, a high serum level of apolipoprotein E (apo E) (but with the heterozygous E 2/3 isoform instead of the E 2/2 isoform), and the absence of the typical clinical features associated with type III hyperlipoproteinemia. The common clinical presentation is the nephrotic syndrome. The characteristic pathologic features are concentrically layered vacuolated lipid "thrombi" in distended glomerular capillary lumens that contain beta/pre-beta lipoprotein. Immunofluorescence studies demonstrate lipoprotein "thrombi" staining for apo E and apo B, but not apo A-I, apo A-II, or apo J. Immunoglobulins, complement, and fibrin are absent or present in trace amounts. The long-term follow-up demonstrates progressive deterioration of renal function despite lipolytic therapy. The apparent predilection of lipoprotein glomerulopathy in Orientals, particularly Japanese subjects, is poorly understood, but appears to be related to genetic factors. The cause of the hyperlipoproteinemia and lipoprotein "thrombi" containing apo E and apo B is unknown, but is possibly related to defective receptor-binding mechanisms.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7985674     DOI: 10.1016/s0272-6386(12)81066-3

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  7 in total

1.  Lipoprotein Glomerulopathy, First Case Report from Canada.

Authors:  Julie Anne Ting; Susanna A McRae; Daniel Schwartz; Sean J Barbour; Maziar Riazy
Journal:  Int J Nephrol Renovasc Dis       Date:  2022-06-21

Review 2.  An Updated Review and Meta Analysis of Lipoprotein Glomerulopathy.

Authors:  Meng-Shi Li; Yang Li; Yang Liu; Xu-Jie Zhou; Hong Zhang
Journal:  Front Med (Lausanne)       Date:  2022-05-06

3.  Improvement of nephrotic syndrome by intensive lipid-lowering therapy in a patient with lipoprotein glomerulopathy.

Authors:  Akira Matsunaga; Masayuki Furuyama; Taeko Hashimoto; Kentaro Toyoda; Daisuke Ogino; Kiyoshi Hayasaka
Journal:  Clin Exp Nephrol       Date:  2009-07-15       Impact factor: 2.801

Review 4.  Lipoprotein glomerulopathy-like disease in a patient with type III hyperlipoproteinemia due to apolipoprotein E2 (Arg158 Cys)/3 heterozygosity.

Authors:  Miho Karube; Kimimasa Nakabayashi; Yasunori Fujioka; Ken Yoshihara; Akira Yamada; Akira Matsunaga; Takao Saito
Journal:  Clin Exp Nephrol       Date:  2007-06-28       Impact factor: 2.801

Review 5.  Metabolism, energetics, and lipid biology in the podocyte - cellular cholesterol-mediated glomerular injury.

Authors:  Sandra Merscher; Christopher E Pedigo; Armando J Mendez
Journal:  Front Endocrinol (Lausanne)       Date:  2014-10-14       Impact factor: 5.555

6.  A case of nephrotic syndrome showing contemporary presence of apolipoprotein E2 homozygote glomerulopathy and membranous nephropathy-like findings modified by apolipoprotein E Toyonaka.

Authors:  Hisako Hirashima; Toshiyuki Komiya; Naoya Toriu; Shigeo Hara; Akira Matsunaga; Takao Saito; Eri Muso
Journal:  Clin Nephrol Case Stud       Date:  2018-11-30

7.  Membranous Nephropathy-Like Apolipoprotein E Deposition Disease with Apolipoprotein E Toyonaka (Ser197Cys) and a Homozygous Apolipoprotein E2/2.

Authors:  Megumu Fukunaga; Kiyotaka Nagahama; Michiko Aoki; Akira Shimizu; Shigeo Hara; Akira Matsunaga; Eri Muso; Takao Saito
Journal:  Case Rep Nephrol Dial       Date:  2018-03-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.